MGMT and glioblastoma: The result showed that there were significant differences in the risk score among GBM patients categorized by age, IDH status, O6-methylguanine-DNA methyltransferase (MGMT) promoter status, molecular subtype, and CIMP status, but no differences between genders (Fig. 4B–G), suggesting a higher level of risk score in subtypes with poorer prognosis of GBM.